Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting
Matthew M Seavey, Yvonne PatersonDepartment of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USAAbstract: Targeting tumors using cancer vaccine therapeutics has several advantages including the induction of long-term immunity, prime boost strategies for additional tr...
Guardado en:
Autores principales: | Matthew M Seavey, Yvonne Paterson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e31ca0e3c7a741ccbd52298d2cf2eba4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
por: Maral Mokhtari, et al.
Publicado: (2021) -
Cancer biomarker HER-2/neu in breast cancer in Indian women
por: Singhai R, et al.
Publicado: (2011) -
Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
por: Vinayak W Patil, et al.
Publicado: (2011) -
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni MA, et al.
Publicado: (2021) -
Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
por: Lower EE, et al.
Publicado: (2017)